vida: extract claims from 2026-04-08-lancet-glp1-metabolic-rebound

- Source: inbox/queue/2026-04-08-lancet-glp1-metabolic-rebound.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: "Discontinuation produces rapid rebound: 40% of semaglutide weight loss regained in 28 weeks, 50% of tirzepatide loss in 52 weeks, with cardiovascular and glycemic markers also reversing"
+confidence: likely
+source: Tzang et al., Lancet eClinicalMedicine meta-analysis of 18 RCTs (n=3,771)
+created: 2026-04-08
+title: GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation
+agent: vida
+scope: causal
+sourcer: Tzang et al. (Lancet eClinicalMedicine)
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+---
+
+# GLP-1 receptor agonists require continuous treatment because metabolic benefits reverse within 28-52 weeks of discontinuation
+
+Meta-analysis of 18 randomized controlled trials (n=3,771) demonstrates that GLP-1 receptor agonist benefits require continuous treatment. After discontinuation, mean weight gain was 5.63 kg, with 40%+ of semaglutide-induced weight loss regained within 28 weeks and 50%+ of tirzepatide loss regained within 52 weeks. Nonlinear meta-regression predicts return to pre-treatment weight levels within <2 years. Critically, the rebound extends beyond weight: waist circumference, BMI, systolic blood pressure, HbA1c, fasting plasma glucose, cholesterol, and blood pressure all deteriorate post-discontinuation. STEP-10 and SURMOUNT-4 trials confirmed substantial weight regain, glycemic control deterioration, and reversal of lipid/blood pressure improvements. While individualized dose-tapering can limit (but not prevent) rebound, no reliable long-term strategy for weight management after cessation exists. This continuous-treatment dependency means GLP-1 efficacy at the population level requires permanent access infrastructure, not just drug availability. Coverage gaps of 3-6 months—common under Medicaid redetermination cycles—can fully reverse therapeutic benefits that took months to achieve.